- Home
- LPA vs NRXP Comparison
LPA vs NRXP Comparison
Compare LPA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPA | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 54.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | LPA | NRXP |
|---|---|---|
| Price | $2.49 | $1.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 9.7K | ★ 487.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.04 | $1.58 |
| 52 Week High | $9.81 | $3.84 |
Technical Indicators
Market Signals| Indicator | LPA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 46.40 |
| Support Level | $2.57 | $1.65 |
| Resistance Level | $2.94 | $1.99 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 67.65 | 46.03 |
Price Performance
Historical ComparisonAbout LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.